Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Ipsen has delivered a 100.7% total return over the past five years, yet there is a clear split in what the valuation work is saying, with a Discounted Cash Flow (DCF) estimate pointing to upside while market multiples suggest the stock is already priced on the rich side.
-
Over five years, Ipsen has returned 100.7%, which puts current holders in a strong position and raises the bar for new buyers looking for further upside.
-
Planned acquisitions of Memo Therapeutics and Kartos Therapeutics can support expectations for future cash flows, but the scale of the deals and associated milestone payments may also increase execution and integration risks that matter for valuation.
-
Ipsen screens as undervalued on the Discounted Cash Flow (DCF) estimate by around 41.3%, yet it only passes 2 of 6 broader valuation checks, which means the stock does not screen as a straightforward bargain on most measures 2.
The issue now is whether Ipsen's current share price better reflects the intrinsic value suggested by the DCF work or the more cautious signal coming from traditional valuation checks and market multiples.
Does Ipsen Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model values Ipsen by projecting its future free cash flows and discounting them back to today. For Ipsen, the latest twelve month free cash flow is about €666.1 million, and the model assumes these cash flows continue to grow rather than contract over time. On that basis, the DCF points to an estimated intrinsic value of around €283 per share, which is higher than the current market price and implies the stock screens as 41.3% undervalued.
The recent agreements to acquire Memo Therapeutics and Kartos Therapeutics add sizeable pipeline optionality, but they also bring substantial milestone commitments that can affect future cash generation. Because the Memo Therapeutics deal in particular involves possible payments of more than €700 million, the market may be applying a discount to Ipsen's cash flow outlook despite what the model suggests.
On balance, the discounted cash flow work indicates Ipsen stock currently appears undervalued relative to its projected cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Ipsen is undervalued by 41.3%. Track this in your watchlist or portfolio , or discover 215 more high quality undervalued stocks .
Has Ipsen Run Too Far on Earnings?
The P/E ratio is a useful yardstick for Ipsen because earnings are a key focus for many investors in the Pharmaceuticals sector. Ipsen currently trades on a P/E of about 30.7x, which is well above the broader Pharmaceuticals industry average of 21.3x and also ahead of the peer group average of 16.4x. That means you are paying a higher price for each euro of Ipsen's earnings than for many comparable stocks.
On Simply Wall St's fair multiple framework, which looks at factors such as growth, margins, size and risk, Ipsen's earnings would line up with a P/E of around 26.2x. Compared with that yardstick, the current 30.7x suggests the stock is pricing in a premium relative to what those fundamentals alone might support.
Overall, Ipsen stock currently appears overvalued on its P/E multiple relative to both tailored and industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Ipsen Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Ipsen's mixed DCF and P/E signals leave off by explaining what would need to happen to Ipsen's growth, margins and earnings for the stock to be worth meaningfully more or less than today's price. They are available on the company's Community page. Each narrative treats fair value as a thesis about Ipsen's business that you can revisit over time, rather than a one-off snapshot.
Community views on Ipsen sit far apart, with one camp leaning into the rare disease and oncology upside while another is more cautious about concentration and execution risk.
Bull case: 21% undervalued
"Ipsen's rare disease pipeline, including imminent Fidrisertib pivotal data in FOP and broadening launches of Bylvay and Iqirvo, is uniquely positioned to benefit from long-term increases in global healthcare spending on specialty pharmaceuticals..."
Read the full Bull Case to see why Ipsen could be undervalued
Bear case: roughly fairly valued
"Ipsen's portfolio demonstrates high revenue concentration in a small number of leading products across oncology, rare disease, and neuroscience, exposing the company to the risk that patent expirations, loss of market exclusivity, or competitive product launches could create sharp and sustained declines in top-line revenue and net earnings..."
Read the full Bear Case to see why Ipsen could be overvalued
Do you think there's more to the story for Ipsen? Head over to our Community to see what others are saying!
The Bottom Line
For Ipsen, the Discounted Cash Flow (DCF) work points to meaningful upside on an intrinsic value basis, while the P/E comparison suggests the stock is already trading at a premium to peers. That split reflects different lenses, with the DCF leaning on future cash flows and the market multiple reflecting current sentiment and growth expectations. Broader valuation checks remain weak despite the DCF signal. The key question is whether Ipsen's pipeline investments and acquisitions eventually translate into the cash generation implied by the intrinsic value estimate, or whether execution and concentration risks justify the current premium.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IPN.PA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
